Goldman Sachs Upgrades Rocket Pharmaceuticals Stock
Rocket Pharmaceuticals (RCKT) saw an increase in stock price on Thursday following Goldman Sachs upgrading the company's rating from Sell to Neutral. The upgrade was based on recent developments regarding RP-A501, a gene therapy candidate for Danon disease, a rare genetic disorder. Goldman Sachs cited positive updates about RP-A501 as a key factor behind its decision. This experimental treatment is in development and could represent an important milestone if it progresses successfully through clinical trials. The upgrade reflects improved sentiment among analysts regarding the company's prospects with this therapy. The market responded positively to the news, indicating investor confidence in Rocket Pharmaceuticals' potential advancements.
Tickers: $RCKT
Topics: Danon disease Goldman Sachs Rocket Pharmaceuticals RP-A501